Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma

• Published in: Japanese journal of ophthalmology 2024-05, Vol.68 (3), p.206-210
• Main Authors: Inoue, Kenji, Shiokawa, Minako, Kunimatsu-Sanuki, Shiho, Kang, Jungshin, Uraki, Takehiko, Tomita, Goji, Ishida, Kyoko
• Format: Article
• Language: English
• Subjects: Algorithms; Clinical Investigation; Deviation; Effectiveness; Glaucoma; Hyperemia; Intraocular pressure; Medicine; Medicine & Public Health; Ophthalmology; Safety; Side effects; Visual field; Visual fields; Visual thresholds
• ISSN: 0021-5155; 1613-2246
• DOI: 10.1007/s10384-024-01052-8

Purpose To retrospectively evaluate the 3-year efficacy and safety of single-agent omidenepag isopropyl in patients with normal tension glaucoma (NTG). Study design Retrospective. Methods One hundred patients (100 eyes) who had newly been administered omidenepag isopropyl were enrolled in this study. Intraocular pressure (IOP) was compared at baseline and 6, 9, 12, 18, 24, 30, and 36 months after administration. The mean deviation values at baseline and 12, 24, and 36 months measured using the Humphrey visual field test (30-2 Swedish Interactive Threshold Algorithm standard) were compared. Adverse reactions and dropouts were assessed. Results IOP significantly decreased from 15.5±2.7 mmHg at baseline to 13.8 ±2.3 mmHg after 6 months, 13.9± 2.3 mmHg after 12 months, 13.9±2.3 mmHg after 18 months, 13.8±2.1 mmHg after 24 months, 13.9±2.0 mmHg after 30 months, and 13.6±1.7 mmHg after 36 months (P < 0.0001). There was no significant difference in the mean deviation values at baseline (-3.66±3.49 dB), 12 months (-3.41±3.80 dB), 24 months (-3.13±3.81 dB), and 36 months (-3.06±3.30 dB). Adverse reactions occurred in 11 patients (11.0%), including conjunctival hyperemia in 6 patients. Fifty-two patients (52.0%) were excluded from the analysis because they discontinued treatment either due to IOP measurement by NCT or the use of additional drugs. Conclusion After the administration of omidenepag isopropyl, IOP in patients with NTG decreased within 3 years, visual fields were maintained, and safety was satisfactory. Thus, omidenepag isopropyl can be used as the first-line treatment for patients with NTG.